Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Overview
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Companies Involved in Therapeutics Development
AgeneBio Inc
Cerevel Therapeutics Holdings Inc
F. Hoffmann-La Roche Ltd
Les Laboratoires Servier SAS
Ono Pharmaceutical Co Ltd
Sanio AB
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Drug Profiles
afizagabar - Drug Profile
Product Description
Mechanism Of Action
History of Events
AGB-473 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
basmisanil - Drug Profile
Product Description
Mechanism Of Action
History of Events
darigabat - Drug Profile
Product Description
Mechanism Of Action
History of Events
ONO-8590580 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RG-7816 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RO-4938581 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GABRA5 for Schizophrenia and Autism - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonise GABRA5 for Cognitive Impairment - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize GABRA5 for Depression - Drug Profile
Product Description
Mechanism Of Action
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Dormant Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Discontinued Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2022: Cerevel Therapeutics announces positive topline results for Darigabat in phase 1 clinical trial in acute anxiety
Jan 28, 2021: Cerevel Therapeutics hosts Iugural Virtual R&D event to review Darigabat (CVL-865) and provide overview of key preclinical programs
Oct 06, 2020: Cerevel Therapeutics announces first patient dosed in phase 2 trial of CVL-865, an investigatiol therapy in development for the treatment of Epilepsy
Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy
Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865
Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigatiol Epilepsy treatment
Oct 09, 2018: AgeneBio Announces NIH grant award to support development of GABA-A a5 small molecule program targeting hippocampal overactivity
Jul 12, 2018: Sanio receives milestone payment from Boehringer Ingelheim
Sep 13, 2017: AgeneBio to Receive up to $10 Million in NIH Funding to Advance Program for Mild Cognitive Impairment Due to Alzheimer’s Disease
Jun 30, 2017: AgeneBio Receives Grant from Alzheimer’s Drug Discovery Foundation for Drug-Discovery Program to Delay the Onset of Alzheimer’s Dementia
Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome
Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AgeneBio Inc, 2022
Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Pipeline by F. Hoffmann-La Roche Ltd, 2022
Pipeline by Les Laboratoires Servier SAS, 2022
Pipeline by Ono Pharmaceutical Co Ltd, 2022
Pipeline by Saniona AB, 2022
Dormant Projects, 2022
Discontinued Products, 2022